Guangzhou Baiyunshan Pharmaceutical Holdings Valuation
Is 600332 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 600332 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 600332 (CN¥28.06) is trading above our estimate of fair value (CN¥15.33)
Significantly Below Fair Value: 600332 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600332?
Key metric: As 600332 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 600332's PE Ratio? | |
|---|---|
| PE Ratio | 7.8x |
| Earnings | CN¥3.42b |
| Market Cap | CN¥43.12b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | 9x |
| PEG Ratio | -19.8x |
Price to Earnings Ratio vs Peers
How does 600332's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16x | ||
000963 Huadong Medicine | 19.1x | 13.2% | CN¥61.4b |
601607 Shanghai Pharmaceuticals Holding | 20x | 18.5% | CN¥71.3b |
600511 China National Medicines | 12.2x | 9.1% | CN¥26.4b |
600998 Jointown Pharmaceutical Group | 12.6x | 17.1% | CN¥25.7b |
600332 Guangzhou Baiyunshan Pharmaceutical Holdings | 7.8x | -0.4% | CN¥46.3b |
Price-To-Earnings vs Peers: 600332 is good value based on its Price-To-Earnings Ratio (7.8x) compared to the peer average (16x).
Price to Earnings Ratio vs Industry
How does 600332's PE Ratio compare vs other companies in the CN Healthcare Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 600332 is good value based on its Price-To-Earnings Ratio (7.8x) compared to the CN Healthcare industry average (34.5x).
Price to Earnings Ratio vs Fair Ratio
What is 600332's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 7.8x |
| Fair PE Ratio | 17.9x |
Price-To-Earnings vs Fair Ratio: 600332 is good value based on its Price-To-Earnings Ratio (7.8x) compared to the estimated Fair Price-To-Earnings Ratio (17.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shenzhen Lifotronic Technology
CN¥6.7b
Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.
688389
CN¥15.53
7D
-5.8%
1Y
-34.9%
Truking Technology
CN¥4.5b
Engages in medical equipment business in China and internationally.
300358
CN¥7.61
7D
0.1%
1Y
-35.9%
Winner Medical
CN¥19.7b
Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.
300888
CN¥33.90
7D
5.4%
1Y
-14.7%